• Kadambari Vijaykumar, George M Solomon, Jennifer Guimbellot, Edward P Acosta, Pradeep G Bhambhavni, Sharon White, Harrison Kim, S Vamsee Raju, Lawrence W Rasmussen, Necole Harris, Bo Liu, Heather Hathorne, Steven M Rowe, and Mark T Dransfield.
• The University of Alabama at Birmingham, Birmingham, Alabama, United States.
• Am. J. Respir. Crit. Care Med. 2024 Sep 24.

RationalePatients with chronic obstructive pulmonary disease (COPD) exhibit acquired cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction. CFTR modulators may improve outcomes in patients with COPD, although recent data regarding magnitude of benefit have been inconclusive and effects on mucociliary clearance are unknown. We conducted a phase 2, randomized, double blind placebo control trial to determine safety and tolerability, and explore the potential mechanism of ivacaftor for the treatment of COPD.MethodsWe randomized 40 patients with moderate to severe COPD and symptoms of chronic bronchitis to ivacaftor (N=30) or placebo (N=10) 150mg BID for 12 weeks. Primary endpoints included evaluation of safety of ivacaftor and pharmacokinetics (PK). Secondary endpoints included measures of CFTR activity and clinical outcomes.ResultsIvacaftor was safe and tolerable with similar rates of adverse events rates between groups. Most common adverse event was diarrhea in the ivacaftor group and acute COPD exacerbation in the placebo group. PK analysis found the mean area under the curve over 12 hours (AUC12) to be 72% of the previously reported AUC12 in cystic fibrosis (CF). Treatment with ivacaftor did not improve sweat chloride, whole lung mucociliary clearance, lung function or respiratory symptoms.ConclusionIvacaftor was safe and well tolerated, but did not improve measures of CFTR activity or mucus clearance. As serum concentrations achieved were lower than observed in CF at the same dose, and modulation of wild type CFTR differs from G551D, further dose determination studies are needed to better understand treatment efficacy of CFTR potentiators in COPD. Clinical trial registration available at www.Clinicaltrialsgov, ID: NCT03085485.

5 keywords...

hide…